Lack of immunomodulating effect of disulfiram on HIV positive patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Lack of immunomodulating effect of disulfiram on HIV positive patients. / Hørding, M; Gøtzsche, P C; Bygbjerg, Ib Christian; Christensen, L D; Faber, V.

In: International Journal of Immunopharmacology, Vol. 12, No. 2, 01.01.1990, p. 145-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hørding, M, Gøtzsche, PC, Bygbjerg, IC, Christensen, LD & Faber, V 1990, 'Lack of immunomodulating effect of disulfiram on HIV positive patients', International Journal of Immunopharmacology, vol. 12, no. 2, pp. 145-7.

APA

Hørding, M., Gøtzsche, P. C., Bygbjerg, I. C., Christensen, L. D., & Faber, V. (1990). Lack of immunomodulating effect of disulfiram on HIV positive patients. International Journal of Immunopharmacology, 12(2), 145-7.

Vancouver

Hørding M, Gøtzsche PC, Bygbjerg IC, Christensen LD, Faber V. Lack of immunomodulating effect of disulfiram on HIV positive patients. International Journal of Immunopharmacology. 1990 Jan 1;12(2):145-7.

Author

Hørding, M ; Gøtzsche, P C ; Bygbjerg, Ib Christian ; Christensen, L D ; Faber, V. / Lack of immunomodulating effect of disulfiram on HIV positive patients. In: International Journal of Immunopharmacology. 1990 ; Vol. 12, No. 2. pp. 145-7.

Bibtex

@article{bcd2823061d34d0a86b2d4cd907d3d4d,
title = "Lack of immunomodulating effect of disulfiram on HIV positive patients",
abstract = "Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.",
keywords = "Adjuvants, Immunologic, Disulfiram, HIV Seropositivity, Humans, Male, Randomized Controlled Trials as Topic, Time Factors",
author = "M H{\o}rding and G{\o}tzsche, {P C} and Bygbjerg, {Ib Christian} and Christensen, {L D} and V Faber",
year = "1990",
month = jan,
day = "1",
language = "English",
volume = "12",
pages = "145--7",
journal = "International Journal of Immunopharmacology",
issn = "0192-0561",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Lack of immunomodulating effect of disulfiram on HIV positive patients

AU - Hørding, M

AU - Gøtzsche, P C

AU - Bygbjerg, Ib Christian

AU - Christensen, L D

AU - Faber, V

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.

AB - Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.

KW - Adjuvants, Immunologic

KW - Disulfiram

KW - HIV Seropositivity

KW - Humans

KW - Male

KW - Randomized Controlled Trials as Topic

KW - Time Factors

M3 - Journal article

C2 - 2184133

VL - 12

SP - 145

EP - 147

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

SN - 0192-0561

IS - 2

ER -

ID: 33891068